Back to mobile site

Heron Therapeutics (HRTX) Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation Achieves Primary Endpoints

June 21, 2018 8:01 AM EDT Send to a Friend
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login